(Q53059695)

11 May 2018

title

Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor. (English)

1 reference

11 May 2018

author name string

Punit Sharma

1

1 reference

11 May 2018

Niraj Naswa

2

1 reference

11 May 2018

Sudhir Suman Kc

3

1 reference

11 May 2018

Luis Andres Alvarado

4

1 reference

11 May 2018

Alok Kumar Dwivedi

5

1 reference

11 May 2018

Yashwant Yadav

6

1 reference

11 May 2018

Rakesh Kumar

7

1 reference

11 May 2018

Ariachery C Ammini

8

1 reference

11 May 2018

Chandrasekhar Bal

9

1 reference

11 May 2018

publication date

17 July 2014

1 reference

11 May 2018

number of pages

9

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

11 May 2018

volume

41

1 reference

11 May 2018

issue

12

1 reference

11 May 2018

page(s)

2194-2202

1 reference

11 May 2018

Epidemiology of neuroendocrine tumours

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Clinical significance of blood chromogranin A measurement in neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

In vitro and in vivo detection of somatostatin receptors in human malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Endocrine pancreatic tumors: factors correlated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2850-3

Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study

21 January 2018

1 reference

12 December 2020

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

1 reference

12 December 2020

Processing of generator-produced 68Ga for medical application.

1 reference

12 December 2020

Positron emission tomography with fluorodeoxyglucose in gastro-entero-pancreatic tumors: diagnostic role and prognostic implications

1 reference

12 December 2020

10.1007/S00259-014-2850-3

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018